BCL11A promotes myeloid leukemogenesis by repressing PU.1 target genes

Area of Science:

• Molecular biology
• Hematology
• Oncology

Background:

• BCL11A is a transcriptional repressor implicated in hematological malignancies.
• Its role in myeloid leukemia development is not fully understood.
• BCL11A is known for its involvement in B-cell development and hemoglobin switching.

Purpose of the Study:

• To elucidate the molecular mechanism of BCL11A in promoting myeloid leukemia.
• To investigate the cooperation between BCL11A and Trib1 in acute myeloid leukemia (AML).
• To identify therapeutic strategies targeting BCL11A in AML.

Main Methods:

• Co-immunoprecipitation and chromatin immunoprecipitation sequencing (ChIP-seq) to identify BCL11A interacting partners and DNA binding sites.
• In vitro and in vivo assays to assess the impact of BCL11A on AML cell proliferation and engraftment.
• Treatment of AML cells with HDAC and LSD1 inhibitors (pracinostat and GSK2879552) to evaluate their efficacy.

Main Results:

• BCL11A cooperates with Trib1 in AML development, promoting proliferation and engraftment.
• BCL11A directly represses PU.1 target genes, including Asb2, Clec5a, and Fcgr3, essential for myeloid differentiation.
• HDAC and LSD1 inhibitors reversed BCL11A's repressive activity, inhibiting AML cell growth both in vitro and in vivo.

Conclusions:

• BCL11A promotes malignant progression in AML by repressing PU.1 transcriptional activity.
• High BCL11A expression correlates with poor prognosis in human AML patients.
• Targeting BCL11A or its corepressors represents a potential therapeutic strategy for AML.